135 related articles for article (PubMed ID: 2355886)
1. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.
Gaynon PS; Bleyer WA; Steinherz PG; Finklestein JZ; Littman P; Miller DR; Reaman G; Sather H; Hammond GD
Med Pediatr Oncol; 1990; 18(4):273-9. PubMed ID: 2355886
[TBL] [Abstract][Full Text] [Related]
2. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Chappell R; Hammond D; Bleyer WA
J Clin Oncol; 1996 Feb; 14(2):389-98. PubMed ID: 8636748
[TBL] [Abstract][Full Text] [Related]
3. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
4. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Coccia PF; Bleyer WA; Lukens JN; Siegel SE; Sather HN; Hammond GD
J Clin Oncol; 1989 Dec; 7(12):1807-15. PubMed ID: 2685179
[TBL] [Abstract][Full Text] [Related]
5. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.
Gaynon PS; Bleyer WA; Steinherz PG; Finklestein JZ; Littman PS; Miller DR; Reaman GH; Sather HN; Hammond GD
Am J Pediatr Hematol Oncol; 1988; 10(1):42-50. PubMed ID: 3056061
[TBL] [Abstract][Full Text] [Related]
6. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
8. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Gandemer V; Auclerc MF; Perel Y; Vannier JP; Le Gall E; Demeocq F; Schmitt C; Piguet C; Stephan JL; Lejars O; Debre M; Jonveaux P; Cayuela JM; Chevret S; Leverger G; Baruchel A;
BMC Cancer; 2009 Jan; 9():14. PubMed ID: 19144139
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
11. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
12. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
[TBL] [Abstract][Full Text] [Related]
13. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
[TBL] [Abstract][Full Text] [Related]
16. Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.
Gaynon PS; Steinherz PG; Bleyer WA; Finklestein JZ; Miller DR; Reaman GH; Sather HN; Hammond GD
Med Pediatr Oncol; 1991; 19(4):221-7. PubMed ID: 2056967
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.
Hijiya N; Gajjar A; Zhang Z; Sandlund JT; Ribeiro RC; Rubnitz JE; Jeha S; Liu W; Cheng C; Raimondi SC; Behm FG; Rivera GK; Relling MV; Pui CH
Leukemia; 2004 Oct; 18(10):1581-6. PubMed ID: 15356657
[TBL] [Abstract][Full Text] [Related]
18. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
20. Induction failure in acute lymphoblastic leukemia of childhood.
Silverman LB; Gelber RD; Young ML; Dalton VK; Barr RD; Sallan SE
Cancer; 1999 Mar; 85(6):1395-404. PubMed ID: 10189148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
